Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions

Clinical and Experimental Rheumatology

Volumn 23, Issue 4, 2005, Pages 469-474

  Edrees, Amr F ^a   Misra, Sounak N ^a   Abdou, Nabih I ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Infliximab; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

INFLIXIMAB; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STUDENT T TEST; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26844553332     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. BRENNAN FM, GIBBONS DL, MITCHELL T, COPE AP, MAINI RN, FELDMAN M: Enhanced expression of TNF receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 1992; 22: 1907-12.
2. DELEURAN BD, CHU C-Q, FIELD M et al.: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor. Arthritis Rheum 1992; 35: 1170-8.
3. SAKLATVALA J: Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-9.
4. SHALABY MR, AGGARWAL BB, RINDERKNECHT E, SVEDERSKY KP, FINKLE BS, PALLADINO MA: Activation of human polymorphonuclear neutrophil function by interferon gamma and tumor necrosis factor. J Immunol 1983; 135: 2069-73.
5. COLLINS T, LAPIERRE LA, FIERS W, STROMINGER JL, POBER JS: Recombinant human tumor necrosis factor increases mRNA endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 1986; 83: 446-50.
6. VILCHEK J, PALOMBELLA VJ, HENRIKSEN-DESTEFANO D et al.: Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986; 163: 632-43.
7. DAYER J-M, BEUTLER B, CERAMI A: Cachectintumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8.
8. KEYSTONE EC: Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin of North Am 2001; 27; 427-43.
9. MAINI R, St. CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumor necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet 1999; 354: 1932-9.
10. LIPSKY PE, van der HEIJDE DMFM, St. CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
11. TETTA C, CAMUSSI G, MODENA V, Di VITTORIO C, BAGLIONI C: Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665-7.
12. St. CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum 2002; 46: 1451-9.
13. van VOLLENHOVEN RF, BRANNEMARK S, KLARESKOG L: Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426-30.
14. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
15. KNIGHT DM, TRINH H, LE J et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
16. CORNILLE F, SHEALY D, D'HAENS G et al.: Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463-73.
17. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-563.
18. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New Engl J Med 2003; 348: 601-8.
19. DAYER JM: Interleukin 1 or tumor necrosis factor-α: Which is the real target in rheumatoid arthritis. J Rheumatol 2002; 29 (Suppl. 65): 10-15.
20. BINGHAM CO: The pathogenesis of rheumatoid arthritis: Pivotal cytokines involved in bone degradation and inflammation. J Rheumatol 2002; 29 (Suppl. 65): 3-9.